Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

With the launch of Wegovy by Danish pharmaceutical giant Novo Nordisk and US major Eli Lilly’s Mounjaro already in ...

Axios VisualsWomen are being prescribed GLP-1 weight-loss drugs at higher rates than men, new data shows.Why it matters: This is another cultural moment when women, especially those approaching ...

The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...

So-called ‘skinny jabs’ are being prescribed to people who don’t need them, with terrifying side effects. How did our ...

Novo Nordisk (NYSE: NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

A new study suggests that popular weight loss medications could significantly benefit patients awaiting kidney transplants.

A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...

At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...